Abstract: Compositions and formulations for hair treatment are provided herein. Methods for hair treatment, such as methods for preventing or treating hair loss or hair thinning, are also provided herein. The methods may promote hair growth, hair restoration or hair thickening, or increase hair density or hair growth rate.

Abstract: A method of analyzing decurling settings for a print request including a plurality of sheets, the method including receiving a real image of a first portion of the plurality of sheets, receiving a first input, displaying one or more decurler settings, and displaying a first augmented image of a stack of the plurality of sheets.

Abstract: A method of analyzing decurling settings for a print request including a plurality of sheets, the method including receiving a real image of a first portion of the plurality of sheets, receiving a first input, displaying one or more decurler settings, and displaying a first augmented image of a stack of the plurality of sheets.

Abstract: A flexible advance system allows users to request and receive advances instantly. The flexible advance system facilitates intra-system transfers between a third-party entity and employee accounts at a third-party system by generating and providing funding instructions to the third-party entity. Funding instructions include a funding amount that the flexible advance system predicts using one or more machine-learned models that account for seasonality and time delays. In executing the instructions from the flexible advance system, the third-party entity transfers funds to its entity account with the third-party system based on the funding amount. Once the flexible advance system receives an indication that the third-party entity has executed the instructions, the flexible advance system authorizes users of the flexible advance system to request short-term advances.

Abstract: The present invention relates to PIKFYVE antisense oligonucleotides (ASOs), pharmaceutical compositions containing them, and methods for treating, inhibiting, suppressing, and preventing neurological diseases with them.

Abstract: A flexible advance system allows users to request and receive advances instantly. The flexible advance system facilitates intra-system transfers between a third-party entity and employee accounts at a third-party system by generating and providing funding instructions to the third-party entity. Funding instructions include a funding amount that the flexible advance system predicts using one or more machine-learned models that account for seasonality and time delays. In executing the instructions from the flexible advance system, the third-party entity transfers funds to its entity account with the third-party system based on the funding amount. Once the flexible advance system receives an indication that the third-party entity has executed the instructions, the flexible advance system authorizes users of the flexible advance system to request short-term advances.

Abstract: Systems and methods are disclosed for monitoring features of a computing device of a distributed computing system using a self-monitoring module. The self-monitoring module can include multiple feature-specific monitoring modules and one or more parent nodes for the feature-specific monitoring modules. A feature-specific monitoring module can identify or detect a fault status change, such as a fault condition or fault resolution, for one or more features. Based on the identified fault conditions or fault resolutions, the feature-specific monitoring module can determine an internal status and communicate an updated status to a parent node.

Abstract: A flexible advance system allows users to request and receive advances instantly. The flexible advance system facilitates intra-system transfers between a third-party entity and employee accounts at a third-party system by generating and providing funding instructions to the third-party entity. Funding instructions include a funding amount that the flexible advance system predicts using one or more machine-learned models that account for seasonality and time delays. In executing the instructions from the flexible advance system, the third-party entity transfers funds to its entity account with the third-party system based on the funding amount. Once the flexible advance system receives an indication that the third-party entity has executed the instructions, the flexible advance system authorizes users of the flexible advance system to request short-term advances.

Abstract: An apprenticeship system enabling all stakeholders involved (apprentice, sponsor/employer, TDA) to access a single system to assist an apprentice through the different phases of apprenticeship journey, including Account Creation, Registration (Application & Preparation), In-Class Training, On-The-Job Training (Personalized Logbook), Membership & Certification and Reporting. An apprenticeship system may be built on a common data model so that information is shared across the system for all users, tasks, and business processes. The system may consolidate all data about the apprentice journey in a single location, allowing for real-time data exchange among stakeholders.

Abstract: Systems and methods are disclosed for monitoring features of a computing device of a distributed computing system using a self-monitoring module. The self-monitoring module can include multiple feature-specific monitoring modules and one or more parent nodes for the feature-specific monitoring modules. A feature-specific monitoring module can identify or detect a fault status change, such as a fault condition or fault resolution, for one or more features. Based on the identified fault conditions or fault resolutions, the feature-specific monitoring module can determine an internal status and communicate an updated status to a parent node.

Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Abstract: Systems and methods are disclosed for monitoring features of a computing device of a distributed computing system using a self-monitoring module. The self-monitoring module can include multiple feature-specific monitoring modules and one or more parent nodes for the feature-specific monitoring modules. A feature-specific monitoring module can identify or detect a fault status change, such as a fault condition or fault resolution, for one or more features. Based on the identified fault conditions or fault resolutions, the feature-specific monitoring module can determine an internal status and communicate an updated status to a parent node.

Abstract: Systems and methods are disclosed for monitoring features of a computing device of a distributed computing system using a self-monitoring module. The self-monitoring module can include multiple feature-specific monitoring modules and one or more parent nodes for the feature-specific monitoring modules. A feature-specific monitoring module can identify or detect a fault status change, such as a fault condition or fault resolution, for one or more features. Based on the identified fault conditions or fault resolutions, the feature-specific monitoring module can determine an internal status and communicate an updated status to a parent node.

Abstract: A compact, high-sensitivity magnetometer, including: an optical interface to accept a linearly polarized first light; a pump light source to produce a circularly polarized pump light; a vapor cell having a sealed vessel containing an alkali-metal gas, a first input port to receive the first light, a second input port to accept the pump light from a direction perpendicular to the first light, and an output port to produce a second light; an electromagnetic source to apply a modulated electromagnetic field to the vapor cell at a direction perpendicular to the first light and the pump light, without using a modulator external to the vapor cell; a second linear polarizer, polarized perpendicular to the first light, the second polarizer to receive the second light and to produce a third light; and a photodetector to receive the third light, to produce an intensity measurement of the third light.

Abstract: A compact, high-sensitivity magnetometer, including: an optical interface to accept a linearly polarized first light; a pump light source to produce a circularly polarized pump light; a vapor cell having a sealed vessel containing an alkali-metal gas, a first input port to receive the first light, a second input port to accept the pump light from a direction perpendicular to the first light, and an output port to produce a second light; an electromagnetic source to apply a modulated electromagnetic field to the vapor cell at a direction perpendicular to the first light and the pump light, without using a modulator external to the vapor cell; a second linear polarizer, polarized perpendicular to the first light, the second polarizer to receive the second light and to produce a third light; and a photodetector to receive the third light, to produce an intensity measurement of the third light.

Abstract: A compact, high-sensitivity magnetometer, including: an optical interface to accept a linearly polarized first light; a pump light source to produce a circularly polarized pump light; a vapor cell comprising a sealed vessel containing an alkali-metal gas, a first input port to receive the first light, a second input port to accept the pump light from a direction perpendicular to the first light, and an output port configured to produce a second light; an electromagnetic source configured to apply an electromagnetic field to the vapor cell at a direction perpendicular to the first light and the pump light; a second linear polarizer, having an axis of polarization perpendicular to the first light, the second polarizer configured to receive the second light and to produce a third light; and a photodetector configured to receive the third light, to produce an intensity measurement of the third light.